Rachid Baz
Researcher

Rachid Baz

Academic Rank: Assistant Member

Overview

Dr. Baz’s research is to develop and investigate new therapeutic agents for the treatment of patients with multiple myeloma. 

Discipline

    • Malignant Hematology
    • Myeloma
    • Chemical Biology and Molecular Medicine Program

Education & Training

    • American University of Beirut, MD
    • Cleveland Clinic Foundation, Resident - Internal Medicine
    • Cleveland Clinic Foundation, Fellow - Hematology and Medical Oncology
Research

Dr. Baz is a very active researcher in the field and specifically, he has an interest in clinical trials investigating new agents for patients with relapsed and refractory multiple myeloma. In addition, Dr. Baz collaborates closely with many different investigators within the Moffitt Myeloma Working Group (MMWG) and within the myeloma scientific community in general with the goal of improving outcomes of patients with plasma cell dyscrasias. For example, most of the currently approved agents in the myeloma field have been evaluated at Moffitt in phase I and II clinical trials.

Publications

  • Yun S, Johnson AC, Okolo ON, Arnold SJ, McBride A, Zhang L, Baz RC, Anwer F. Waldenström Macroglobulinemia: Review of Pathogenesis and Management. Clin Lymphoma Myeloma Leuk. 2017 May;17(5):252-262. Pubmedid: 28366781. Pmcid: PMC5413391.
  • Baz RC, Zonder JA, Gasparetto C, Reu FJ, Strout V. Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma. Oncol Ther. 2017 Mar;4(2):287-301. Pubmedid: 28261656. Pmcid: PMC5315068.
  • Rollison DE, Komrokji R, Lee JH, Hampras S, Fulp W, Fisher K, Baz R, Nishihori T, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Sullivan D, Alsina M, Dalton W, Shain KH. Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide. Leuk Lymphoma. 2017 Mar;58(3):560-568. Pubmedid: 27424609.
  • Kuruvilla J, Savona M, Baz R, Mau-Sorensen M, Gabrail N, Garzon R, Stone R, Wang M, Savoie L, Martin P, Flinn I, Jacoby M, Unger TJ, Saint-Martin JR, Rashal T, Friedlander S, Carlson R, Kauffman M, Shacham S, Gutierrez M. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 2017 Jun;129(24):3175-3183. Pubmedid: 28468797.
  • Silva AS, Silva MC, Sudalagunta P, Distler AI, Jacobson T, Collins A, Nguyen T, Song J, Chen DT, Chen L, Cubitt CL, Baz R, Perez L, Rebatchouk D, Dalton W, Greene J, Gatenby RA, Gillies RJ, Sontag E, Meads MB, Shain K. An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma. Cancer Res. 2017 Jun;77(12):3336-3351. Pubmedid: 28400475.
  • Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, Lesokhin AM, Wack C, Charpentier E, Campana F, Vij R. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017 Jun;129(25):3294-3303. Pubmedid: 28483761. Pmcid: PMC5482100.
  • Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, Savoie L, Mau-Sorensen M, Wagner-Johnston N, Yee K, Unger TJ, Saint-Martin JR, Carlson R, Rashal T, Kashyap T, Klebanov B, Shacham S, Kauffman M, Stone R. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017 Jun;129(24):3165-3174. Pubmedid: 28336527.
  • Brayer J, Baz R. The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. Ther Adv Hematol. 2017 Jul;8(7):209-220. Pubmedid: 28694935. Pmcid: PMC5495505.
  • Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017 Jan;18(1):112-121. Pubmedid: 27927582.
  • Baz RC, Martin TG, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 May;127(21):2561-2568. Pubmedid: 26932802.
  • Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann MA, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala HM, Hogan K, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan DM, Landgren O, Grant S. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2016 Mar;22(5):1067-1075. Pubmedid: 26446942. Pmcid: PMC4775365.
  • Siegel DS, Weisel KC, Dimopoulos MA, Baz R, Richardson P, Delforge M, Song KW, San Miguel JF, Moreau P, Goldschmidt H, Cavo M, Jagannath S, Yu X, Hong K, Sternas L, Zaki M, Palumbo A. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leuk Lymphoma. 2016 Dec;57(12):2833-2838. Pubmedid: 27267105.
  • Turner JG, Dawson JL, Grant S, Shain KH, Dalton WS, Dai Y, Meads M, Baz R, Kauffman M, Shacham S, Sullivan DM. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol. 2016 Aug;9(1):73. Pubmedid: 27557643. Pmcid: PMC4997728.
  • Hassoun Y, Kharfan-Dabaja MA, Baz R. Bortezomib plus dexamethasone results in a late organ response in primary heavy-chain amyloidosis without a hematologic response. Hematol Oncol Stem Cell Ther. 2015 Sep;8(3):138-139. Pubmedid: 25732670.
  • Baz R, Lin HM, Hui AM, Harvey RD, Colson K, Gallop K, Swinburn P, Laubach J, Berg D, Richardson P. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. Support Care Cancer. 2015 Sep;23(9):2789-2797. Pubmedid: 25708126.
  • Dimopoulos MA, Swern AS, Li JS, Hussein M, Weiss L, Nagarwala Y, Baz R. Response to letter, 'immortal time bias in retrospective analysis'. Blood Cancer J. 2015 Sep;5:e327. Pubmedid: 26230951. Pmcid: PMC4526781.
  • Griffin PT, Ho VQ, Fulp W, Nishihori T, Shain KH, Alsina M, Baz RC. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. Cancer. 2015 Oct;121(20):3622-3630. Pubmedid: 26149422.
  • Nishihori T, Baz R, Shain K, Kim J, Ochoa-Bayona JL, Yue B, Sullivan D, Dalton W, Alsina M. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma. Eur J Haematol. 2015 Nov;95(5):426-435. Pubmedid: 25600676. Pmcid: PMC4508238.
  • Remily-Wood ER, Benson K, Baz RC, Chen YA, Hussein M, Hartley-Brown MA, Sprung RW, Perez B, Liu RZ, Yoder S, Teer J, Eschrich SA, Koomen JM. Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients. Proteom Clin Appl. 2014 Oct;8(9-10):783-795. Pubmedid: 24723328. Pmcid: PMC4302417.
  • Holkova B, Kmieciak M, Perkins EB, Bose P, Baz R, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson JL, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala HM, Hogan K, Colevas AD, Doyle A, Figg WD, Coppola D, Roberts JD, Sullivan DM, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014 Nov;20(22):5652-5662. Pubmedid: 25248382. Pmcid: PMC4233160.
  • Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson K. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar;123(12):1826-1832. Pubmedid: 24421329. Pmcid: PMC3962162.
  • Baz RC, Shain KH, Hussein MA, Lee JH, Sullivan DM, Finleyoliver E, Nardelli LA, Nodzon LA, Zhao X, Ochoa-Bayona JL, Nishihori T, Dalton WS, Alsina M. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma. Am J Hematol. 2014 Jan;89(1):62-67. Pubmedid: 24030918. Pmcid: PMC4522918.
  • Khin ZP, Ribeiro ML, Jacobson T, Hazlehurst L, Perez L, Baz R, Shain K, Silva AS. A preclinical assay for chemosensitivity in multiple myeloma. Cancer Res. 2014 Jan;74(1):56-67. Pubmedid: 24310398. Pmcid: PMC3915502.
  • Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014 Aug;124(7):1038-1046. Pubmedid: 24920586. Pmcid: PMC4574453.
  • Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 Aug;27:62-73. Pubmedid: 24631834. Pmcid: PMC4108511.
  • Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, Sullivan D, Jim HS, Anasetti C, Alsina M. Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. Bone Marrow Transplant. 2013 Sep;48(9):1179-1184. Pubmedid: 23542223. Pmcid: PMC4500071.
  • Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B. Sequence of novel agents in multiple myeloma: an instrumental variable analysis. Leuk Res. 2013 Sep;37(9):1077-1082. Pubmedid: 23809054.
  • Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar;121(11):1961-1967. Pubmedid: 23243282. Pmcid: PMC4123324.
  • Nishihori T, Abu Kar SM, Baz R, Alsina M, Harousseau JL, Kharfan-Dabaja MA. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013 Feb;19(8):1144-1151. Pubmedid: 23416092.
  • Boucher K, Parquet N, Widen R, Shain K, Baz R, Alsina M, Koomen J, Anasetti C, Dalton W, Perez LE. Stemness of B-cell progenitors in multiple myeloma bone marrow. Clin Cancer Res. 2012 Nov;18(22):6155-6168. Pubmedid: 22988056. Pmcid: PMC3500436.
  • Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Brit J Haematol. 2012 Jun;157(5):553-563. Pubmedid: 22449149. Pmcid: PMC4030553.
  • Jacobsen PB, Wells KJ, Meade CD, Quinn GP, Lee JH, Fulp WJ, Gray JE, Baz RC, Springett GM, Levine RM, Markham MJ, Schreiber FJ, Cartwright TH, Burke JM, Siegel RD, Malafa MP, Sullivan D. Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicenter randomized controlled trial. J Clin Oncol. 2012 Jul;30(20):2516-2521. Pubmedid: 22614993. Pmcid: PMC4577714.
  • Hartley-Brown MA, Sullivan DM, Baz R. State-of-the-Art Management of Complications of Myeloma and Its Treatment. Adv Hematol. 2011 Jul;2010:343089. Pubmedid: 20671999. Pmcid: PMC2905716.
  • Chen F, Pisklakova A, Li M, Baz R, Sullivan DM, Nefedova Y. Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma. Cell Oncol (Dordr). 2011 Dec;34(6):545-551. Pubmedid: 21965140. Pmcid: PMC3417352.
  • Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D, Ochoa-Bayona JL, Kharfan-Dabaja MA, Baz R. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):507-511. Pubmedid: 21813352.
  • Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype. Mol Cancer Ther. 2011 Dec;10(12):2257-2266. Pubmedid: 21980133. Pmcid: PMC3237739.
  • Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, Bello CM, Chervenick PA, Bruno S, Cultrera JL, Baz RC, Kharfan-Dabaja MA, Raychaudhuri J, Sotomayor EM, Sokol L. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011 Dec;35(12):1571-1577. Pubmedid: 21752466.
  • Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010 Nov;24 Suppl 1:S13-S19. Pubmedid: 21126632.
  • Hartley MA, Tao J, Baz R. Merkel cell carcinoma in the peripheral blood of a patient with concomitant chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol. 2010 Mar;28(7):e113-e114. Pubmedid: 20008639.
  • Baz R, Patel M, Finley-Oliver E, Lebovic D, Hussein MA, Miller KC, Wood M, Sher T, Lee K, Chanan-Khan AA. Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leuk Lymphoma. 2010 Jun;51(6):1015-1019. Pubmedid: 20367570. Pmcid: PMC4046695.
  • Mourad AR, Kharfan-Dabaja MA, Benson K, Moscinski LC, Baz RC. Leptomeningeal myeloma as the sole manifestation of relapse: an unusual presentation. Am J Med Sci. 2010 Jan;339(1):81-82. Pubmedid: 19875952.
  • Khoriaty R, Hussein MA, Faiman B, Kelly M, Kalaycio M, Baz R. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions. Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):E10-E13. Pubmedid: 20223721.
  • Kelley TW, Baz R, Hussein M, Karafa M, Cook JR. Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen. Hum Pathol. 2009 Mar;40(3):405-412. Pubmedid: 19070887.
  • Rodriguez C, Baz R, Jawde R, Rybicki L, Kalaycio M, Advani A, Sobecks R, Sekeres M. Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia. Leuk Res. 2008 Mar;32(3):413-420. Pubmedid: 17727945.
  • Choueiri T, Baz R, McFadden C, Khasawneh M, Karam M, Kelly M, Hussein M. An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. Bju Int. 2008 Mar;101(6):712-715. Pubmedid: 17970789.
  • Advani AS, Rodriguez C, Jin T, Jawde RA, Saber W, Baz R, Kalaycio M, SobecksR, Sekeres M, Tripp B, Hsi E. Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. Leuk Res. 2008 Jun;32(6):913-918. Pubmedid: 17928050.
  • Cheriyath V, Glaser KB, Waring JF, Baz R, Hussein MA, Borden EC. G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J Clin Invest. 2007 Oct;117(10):3107-3117. Pubmedid: 17823654. Pmcid: PMC1964509.
  • Baz R, Rodriguez C, Fu A, Jawde R, Kalaycio M, Advani A, Sobecks R, SekeresMA. Impact of remission induction chemotherapy on survival in older adults with acutemyeloid leukemia. Cancer. 2007 Oct;110(8):1752-1759. Pubmedid: 17724726.
  • Choueiri T, Rini B, Garcia J, Baz R, Abou-Jawde R, Thakkar S, Elson P, Mekhail T, Zhou M, Bukowski R. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Ann Oncol. 2007 Feb;18(2):249-255. Pubmedid: 17060490.
  • Baz R, Fanning S, Kunkel L, Gaballa S, Karam MA, Reed J, Kelly M, Hussein M. Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma. Leuk Lymphoma. 2007 Dec;48(12):2338-2344. Pubmedid: 18067008.
  • Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007 Aug;110(3):543-550. Pubmedid: 17577222.
  • Baz R, Walker E, Choueiri T, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein M. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol. 2007;117(3):162-167. Pubmedid: 17148935.
  • Abou-Jawde R, Baz R, Walker E, Choueiri T, Karam M, Reed J, Faiman B, Hussein M. The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica. 2006 Oct;91(10):1410-1413. Pubmedid: 16963396.
  • Hussein M, Baz R, Srkalovic G, Agrawal N, Suppiah R, Hsi E, Andresen S, Karam M, Reed J, Faiman B, Kelly M, Walker E. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc. 2006 Jul;81(7):889-895. Pubmedid: 16835968.
  • Choueiri T, Dreicer R, Rini B, Elson P, Garcia J, Thakkar S, Baz R, Mekhail T, Jinks H, Bukowski R. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer. 2006 Dec;107(11):2609-2616. Pubmedid: 17075879.
  • Baz R, Walker E, Karam M, Choueiri T, Jawde R, Bruening K, Reed J, FaimanB, Ellis Y, Brand C, Srkalovic G, Andresen S, Knight R, Zeldis J, Hussein M. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 2006 Dec;17(12):1766-1771. Pubmedid: 16980599.
  • Baz R, Hussein M. Does low-dose aspirin have antineoplastic effects in multiple myeloma?. Brit J Haematol. 2006 Aug;134(3):349-350. Pubmedid: 16848779.
  • Abou-Jawde R, Reed J, Kelly M, Walker E, Andresen S, Baz R, Karam M, Hussein M. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol. 2006;23(2):263-272. Pubmedid: 16720927.
  • Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, Karam M, Faiman B, Jawde R, Andresen S, Zeldis J, Hussein M. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005 Dec;80(12):1568-1574. Pubmedid: 16342649.
  • Baz R, Alemany C, Green R, Hussein M. Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review. Cancer. 2004 Aug;101(4):790-795. Pubmedid: 15305411.